I nuovi anticoagulanti orali: Raccomandazioni, precauzionie prospettive d'uso

Translated title of the contribution: New oral anticoagulants: Recommendations, precautions and prospects of use

Giovanni Di Minno, Anna Russolillo, Itala Ventre, Alessandro Di Minno, Domenico Prisco

Research output: Contribution to journalArticlepeer-review


In phase III studies, some oral inhibitors of both thrombin (dabigatran etexilate) and activated factor X (rivaroxaban, apixaban) have been employed as new anticoagulant drugs in patients with atrial fibrillation or acute coronary syndromes. Such new drugs have overcome a series of limitations of the standard-of-care warfarin, and argue for the possibility of an easy, widespread use of anticoagulation in vascular medicine. However, to this end, we need information on management of bleeding in patients receiving these drugs. Dabigatran etexilate, rivaroxaban and apixaban affect major laboratory tests for clotting. However, at present we do not know whether and how this information may be clinically useful. Their high cost is another major issue, and newer pharmacoeconomic studies are needed to evaluate their cost-effectiveness ratio vs warfarin.

Translated title of the contributionNew oral anticoagulants: Recommendations, precautions and prospects of use
Original languageItalian
JournalGiornale Italiano di Cardiologia
Issue number11 SUPPL.1
Publication statusPublished - Nov 2012

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'New oral anticoagulants: Recommendations, precautions and prospects of use'. Together they form a unique fingerprint.

Cite this